Initial therapy of multiple myeloma in patients who are candidates for stem cell transplantation

被引：4

作者：

Bensinger W. ^{[1
]}

机构：

[1] Fred Hutchinson Cancer Research Center, Seattle, WA 98118

来源：

Current Treatment Options in Oncology | 2007年 / 8卷 / 2期

关键词：

Multiple Myeloma; Thalidomide; Bortezomib; Lenalidomide; Autologous Stem Cell Transplantation;

D O I：

10.1007/s11864-007-0027-z

中图分类号：

学科分类号：

摘要：

Multiple myeloma (MM), a B cell hematologic malignancy involving plasma cells, responds to a variety of drugs including alkylators, steroids, anthracyclines, immunomodulators and proteosome inhibitors. The disease, however, remains largely incurable for the majority of patients. For patients who are suitable candidates, high dose chemotherapy with autologous stem cell support (ASCT) after induction therapy has been shown to improve response rates, progression free survival and overall survival compared to conventional chemotherapy. The availability of new drugs including thalidomide, lenalidomide and bortezomib has rapidly changed induction strategies. These drugs have been combined with corticosteroids, alkylators and anthracyclines to treat front-line patients with MM. Preliminary, phase 1-2 studies have indicated very high response rates and complete response rates formerly only seen with ASCT. Emerging data from randomized trials suggest that older regimens such as vincristine, adriamycin and dexamethasone (VAD) are not as effective for induction as newer combinations. Thus new regimens incorporating novel agents should improve overall response rates, increase complete responders which should translate into improved progression free and overall survival. © Current Science Inc. 2007.

引用

页码：135 / 143

页数：8

共 33 条

[1]

Child J.A., Morgan G.J., Davies F.E., Et al., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 348, pp. 1875-1883, (2003)

[2]

Kumar S., Anderson K.C., Drug insight: Thalidomide as a treatment for multiple myeloma (Review), Nat Clin Pract Oncol, 2, pp. 262-270, (2005)

[3]

Anderson K.C., Shaughnessy Jr. J.D., Barlogie B., Et al., Multiple myeloma, Hematology 2002: American Society of Hematology Education Program Book, pp. 214-240, (2002)

[4]

Attal M., Harousseau J.-L., Stoppa A.-M., Et al., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma, N Engl J Med, 335, pp. 91-97, (1996)

[5]

Lahuerta J.J., Martinez-Lopez J., Serna J.D., Et al., Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients, Br J Haematol, 109, pp. 438-446, (2000)

[6]

Alexanian R., Weber D., Giralt S., Et al., Impact of complete remission with intensive therapy in patients with responsive multiple myeloma, Bone Marrow Transplant, 27, pp. 1037-1043, (2001)

[7]

Davies F.E., Forsyth P.D., Rawstron A.C., Et al., The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma, Br J Haematol, 112, pp. 814-819, (2001)

[8]

Harousseau J.-L., Attal M., Moreau P., Et al., The prognostic imapct of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM). Combined results of the IFM 99 trials, Blood, 108, PART 1, (2006)

[9]

Wang M., Delasalle K., Thomas S., Et al., Complete remission represents the major surrogate marker of long survival in multiple myeloma, Blood, 108, PART 1, (2006)

[10]

Corradini P., Cavo M., Lokhorst H., Et al., Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma, Blood, 102, pp. 1927-1929, (2003)

← 1 2 3 4 →